Total Articles:
886,158 Total Authors:
151,791 Total Downloads:
19,356,238
Newest Member Malka Ladick
Text Ad's
Fluoroquinolone Antibiotics Classification, Uses and Side Effects The fluoroquinolones are a relatively new groupping antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a session of antibiotics, whose acc
The fluoroquinolones certainly are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, taken from 1962 by Lescher and colleagues. The earliest fluoroquinolones were often basically because they were the sole orally administered agents an alternative for handling serious infections caused by gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones possess a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important part in treating community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in kids
Newer quinolones produce additional toxicities towards the heart which were not found in the older elements
Fluoroquinolones advantages:
Simplicity of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a small discount in activity against gram-negative bacteria. Their expanded gram-positive activity is incredibly important this is because includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, understanding the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were chosen primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing in comparison to the newer quinolones, and they are more susceptible to the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications inside the remedy for complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of the availability in oral and intravenous formulations and their broad set of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated right into a third class owing to their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. While the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species.
Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are useful inside the remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. Additionally retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Owing to concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), as well as the drug is necessary for not any longer than 14 days.
Negative effects
The fluoroquinolones to be a class is usually well tolerated. Most adverse reactions are mild in severity, self-limited, and barely result in treatment discontinuation. However, they could have serious uncomfortable side effects.
Fluoroquinolones are approved for use only in people older than 18. They will be able to affect the increase of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the possibility to cause teratogenic or embryocidal effects. Giving fluoroquinolones during your pregnancy is not really recommended unless the positive aspects justify inpending risks towards the fetus. These agents can also be excreted in breast milk and will be ignored during breast-feeding if it is possible.
Gastrointestinal effects. The commonest negative effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have already been reported to all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones really should be avoided in patients which has a roots or history of convulsion, cerebral trauma, or anoxia. No seizures are actually reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness took place in about 50% of the patients.
Phototoxicity. Experience with ultraviolet A rays from direct or indirect sunlight should really be avoided during treatment and a number of other days (5 days with sparfloxacin) following the consumption of clonazepam. The degree of phototoxic potential of fluoroquinolones can be as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Be worried about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and then in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures are actually reported provided that nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant by using corticosteroids.
Hepatoxicity. Trovafloxacin use continues to be connected with rare liver damage, which prompted the withdrawal of your oral preparations that came from the U.S. market. However, the IV preparation remains an alternative for treatment of infections so serious the fact that benefits outweigh the risks.
Cardiovascular effects. The newer quinolones are actually found to supply additional toxicities to the heart which were not found together with the older compounds. Evidence means that sparfloxacin and grepafloxacin can have essentially the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia is reported with other fluoroquinolones (levofloxacin and moxifloxacin), the results seem to have been mild.
Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and can be mild to moderate in severity, and typically resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a very wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones posses important aspect in handling community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones range from 3 -20 hours, allowing for once or twice daily dosing.
Author Resource:-
The fluoroquinolones are a breed of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The very first fluoroquinolones were usually mainly because they were the sole orally administered agents available for the treatment of serious infections as a result of gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones possess a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones posses important role in managing community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in kids
Newer quinolones produce additional toxicities to the heart that were not found together with the older brokers
Fluoroquinolones advantages:
Ease of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a large choice of both gram-positive and gram-negative bacteria. Modern-day fluoroquinolones have enhanced activity against gram-positive bacteria with just the a decreased discount in activity against gram-negative bacteria. Their expanded gram-positive activity is very important this is because includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, knowing the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were chosen primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they're more susceptible to the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications within the treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin would be the hottest second-generation quinolones owing to their availability in oral and intravenous formulations and the broad set of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated into a third class owing to their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens similar to Mycoplasma pneumoniae and Chlamydia pneumoniae. Even though third-generation agents retain broad gram-negative coverage, they're less active than ciprofloxacin against Pseudomonas species.
Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful throughout treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that happen to be their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. Additionally retain activity against Pseudomonas species akin to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Due to worry about hepatotoxicity, trovafloxacin therapy ought to be kept for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for no longer than 14 days.
Unwanted side effects
The fluoroquinolones being a class are generally well tolerated. Most negative effects are mild in severity, self-limited, and infrequently set off treatment discontinuation. However, they could have serious uncomfortable side effects.
Fluoroquinolones are approved for use only in people older than 18. They could affect the expansion of bones, teeth, and cartilage inside a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating when these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during your pregnancy will not be recommended unless the advantages justify the new risks towards the fetus. These agents can be excreted in breast milk and will be avoided during breast-feeding whether possible.
Gastrointestinal effects. The commonest side effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have been reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones ought to be avoided in patients by using a history of convulsion, cerebral trauma, or anoxia. No seizures seem to have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms such as dizziness happened about 50% of the patients.
Phototoxicity. Knowledge of ultraviolet A rays from direct or indirect sunlight should really be avoided during treatment and several days (5 days with sparfloxacin) following the consumption of prescription. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Concern about the creation of musculoskeletal effects, evident in animal studies, has led into the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures seem to have been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant utilization of corticosteroids.
Hepatoxicity. Trovafloxacin use has been connected with rare liver damage, which prompted the withdrawal of a typical oral preparations out of your U.S. market. However, the IV preparation continues to be an alternative for remedy for infections so serious which the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones have already been found to provide additional toxicities to the heart which were not found together with the older compounds. Evidence advices that sparfloxacin and grepafloxacin can have essentially the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia seem to have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the results have been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and tend to be mild to moderate in severity, and frequently resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important role in handling community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of many fluoroquinolones be 3 -20 hours, letting maybe once or twice daily dosing.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites